Table 2.

Details of 14 vascular events among patients with ET and platelet count ≥1500 × 109/L at diagnosis of ET

EventType of eventThrombosis or hemorrhage before eventAge at event (y)/sexDriver mutationRevised IPSET-thrombosis at diagnosisPlatelet count/leukocyte count at eventCV risk factorsTherapy at the time of event
CytoreductionAspirinAnticoagulation
Arterial thrombosis 
 #1 TIA None 44/Male CALR type 1 Very low 1520 × 109/L/ 7.7 × 109/L None Anagrelide None None 
 #2* MI None 55/Female CALR type 2 Very low NA HTN Hydroxyurea None None 
 #3† CVA Splenic venous thrombosis DVT 56/Female JAK2 High 1100 × 109/L/ 7.9 × 109/L None Hydroxyurea 81 mg None 
 #4 MI CVA 57/Female JAK2 High 585 × 109/L/ 12.7 × 109/L HTN DM Hydroxyurea 81 mg None 
 #5‡ MI None 87/Male JAK2 High 1185 × 109/L/ 19.9 × 109/L HTN None 81 mg None 
Venous thrombosis 
 #6 Portal vein thrombosis None 50/Female CALR type 2 Very low 299 × 109/L/ 7.4 × 109/L None None None None 
 #7† PE Splenic venous thrombosis Post splenectomy DVT CVA 63/Female JAK2 High 565 × 109/L/ 8.1 × 109/L None Hydroxyurea 81 mg None 
Major hemorrhage      Acquired vWD    
 #8 Lower extremity hematoma None 46/Female CALR type 2 Very low 1757 × 109/L/ 12.1 × 109/L  Ristocetin cofactor activity 32% None None None 
 #9 GI DVT 73/Female JAK2 Low 489 × 109/L/ 4.1 × 109/L NA None 81 mg Warfarin 
 #10* Postoperative MI 59/Female CALR type 2 Very low NA NA Hydroxyurea None None 
 #11† Epistaxis Splenic venous thrombosis DVT CVA PE 64/Female JAK2 High 1134 × 109/L/ 11 × 109/L NA Hydroxyurea 325 mg Warfarin 
 #12 GI PE 54/Male JAK2 High NA NA None None Warfarin 
 #13 Lower extremity hematoma None 92/Female JAK2 High 162 × 109/L/ 8.8 × 109/L NA None None None 
EventType of eventThrombosis or hemorrhage before eventAge at event (y)/sexDriver mutationRevised IPSET-thrombosis at diagnosisPlatelet count/leukocyte count at eventCV risk factorsTherapy at the time of event
CytoreductionAspirinAnticoagulation
Arterial thrombosis 
 #1 TIA None 44/Male CALR type 1 Very low 1520 × 109/L/ 7.7 × 109/L None Anagrelide None None 
 #2* MI None 55/Female CALR type 2 Very low NA HTN Hydroxyurea None None 
 #3† CVA Splenic venous thrombosis DVT 56/Female JAK2 High 1100 × 109/L/ 7.9 × 109/L None Hydroxyurea 81 mg None 
 #4 MI CVA 57/Female JAK2 High 585 × 109/L/ 12.7 × 109/L HTN DM Hydroxyurea 81 mg None 
 #5‡ MI None 87/Male JAK2 High 1185 × 109/L/ 19.9 × 109/L HTN None 81 mg None 
Venous thrombosis 
 #6 Portal vein thrombosis None 50/Female CALR type 2 Very low 299 × 109/L/ 7.4 × 109/L None None None None 
 #7† PE Splenic venous thrombosis Post splenectomy DVT CVA 63/Female JAK2 High 565 × 109/L/ 8.1 × 109/L None Hydroxyurea 81 mg None 
Major hemorrhage      Acquired vWD    
 #8 Lower extremity hematoma None 46/Female CALR type 2 Very low 1757 × 109/L/ 12.1 × 109/L  Ristocetin cofactor activity 32% None None None 
 #9 GI DVT 73/Female JAK2 Low 489 × 109/L/ 4.1 × 109/L NA None 81 mg Warfarin 
 #10* Postoperative MI 59/Female CALR type 2 Very low NA NA Hydroxyurea None None 
 #11† Epistaxis Splenic venous thrombosis DVT CVA PE 64/Female JAK2 High 1134 × 109/L/ 11 × 109/L NA Hydroxyurea 325 mg Warfarin 
 #12 GI PE 54/Male JAK2 High NA NA None None Warfarin 
 #13 Lower extremity hematoma None 92/Female JAK2 High 162 × 109/L/ 8.8 × 109/L NA None None None 

CV, cardiovascular; CVA, cerebrovascular accident; DM, diabetes mellitus; DVT, deep venous thrombosis; GI, gastrointestinal; HTN, hypertension; IPSET-thrombosis, International prognostic score for thrombosis in ET; MI, myocardial infarction; NA, not available; PE, pulmonary embolism; TIA, transient ischemic attack; vWD, acquired von Willebrand disease.

*

Same patient experienced events 2 and 10.

†

Same patient experienced events 3, 7, and 11.

‡

Same patient experienced events 5 and 14.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal